CHICAGO--(BUSINESS WIRE)--A key milestone in the imaging of Alzheimer’s Disease (AD) has been reached through a close collaboration between radiochemists from the University of Pittsburgh and GE Healthcare. The University of Pittsburgh has started a study aimed at obtaining preliminary information on the performance of flourine-18 labelled Pittsburgh Compound B (F-18 PiB) to identify amyloid deposits in subjects with a diagnosis of AD. Chet Mathis, Professor Of Radiology, University of Pittsburgh School of Medicine and director of the PET Facility at UPMC reports, “early results are encouraging and we look forward to the larger multi-site trials that GE Healthcare will perform with F-18 PiB in early 2007.”
